Selecting the right stocks is Paramount to success ... which rises when the tech-heavy index falls. However, the real draw for day traders is the outsized leverage the fund utilizes to amplify ...

Along with conducting plenty of research, I rely on my experience to draw out the most important trends and likely winners for the best stocks to buy. I've covered this story for over a decade now ...

The right online broker can help you execute your investment strategy and make trading cheap stocks seamless. Take a look at some of Benzinga’s favorites. You have found stocks to buy now cheap ...

As a writer, Michael has covered everything from stocks to cryptocurrency and ETFs for many of the world's m... See Full Bio Michael AdamsCryptocurrency and Investing Expert Editor Michael Adams ...

These are some of the best-performing stocks in the health care sector over the past month Nathan Reiff has been writing expert articles and news about financial topics such as investing and ...

Should you have international stocks in your portfolio? If you already have exposure to US large-cap stocks, international stocks could be a logical addition thanks to their potential to improve ...

[BRIEFING.COM] The stock market started the fourth quarter on a weak note. There are growing expectations for consolidation activity after a stellar third quarter and today's headlines provided fuel.

Looking ahead to 2024, the company is planning its largest-ever exploration program that could potentially serve as a bullish catalyst for the stock. One of the best-performing gold producers.

The telecom giant's high yield appears sustainable, which should attract investors as interest rates come down.

CV Pad, the cutting edge launchpad backed by industry giants CV VC, CV Labs, and DuckDAO, has achieved a major milestone with the successful launch of its first three Initial DEX Offerings (IDOs).

The comments from President and COO Daniel Pinto helped push JPMorgan shares 5.2% lower. Earlier in the year, CEO Jamie Dimon suggested to investors that he thinks the bank's stock is overvalued.

The stock has more than doubled in 2024 but is still trading under $5. Investors are growing increasingly optimistic that imetelstat could gain additional approvals. Geron is in phase 3 clinical ...